196 related articles for article (PubMed ID: 30321870)
21. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
22. Comparison of Ultrasound Features With Maximum Standardized Uptake Value Assessed by 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Prognosis of Estrogen Receptor+/Human Epithelial Growth Factor Receptor 2- Breast Cancer.
Choi B
Ultrasound Q; 2021 Nov; 38(1):18-24. PubMed ID: 35239627
[TBL] [Abstract][Full Text] [Related]
23. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Candelaria RP; Spak DA; Rauch GM; Huo L; Bassett RL; Santiago L; Scoggins ME; Guirguis MS; Patel MM; Whitman GJ; Moulder SL; Thompson AM; Ravenberg EE; White JB; Abuhadra NK; Valero V; Litton J; Adrada BE; Yang WT
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S35-S41. PubMed ID: 34272161
[TBL] [Abstract][Full Text] [Related]
24. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from
Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1787-1795. PubMed ID: 28616695
[TBL] [Abstract][Full Text] [Related]
25.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
26. Triple-negative breast cancer: Pretreatment magnetic resonance imaging features and clinicopathological factors associated with recurrence.
Lee YJ; Youn IK; Kim SH; Kang BJ; Park WC; Lee A
Magn Reson Imaging; 2020 Feb; 66():36-41. PubMed ID: 31785544
[TBL] [Abstract][Full Text] [Related]
27. Predicting the level of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: Usefulness of breast MRI computer-aided detection and diagnosis.
Ku YJ; Kim HH; Cha JH; Shin HJ; Chae EY; Choi WJ; Lee HJ; Gong G
J Magn Reson Imaging; 2018 Mar; 47(3):760-766. PubMed ID: 28675570
[TBL] [Abstract][Full Text] [Related]
28. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
[TBL] [Abstract][Full Text] [Related]
29. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI.
Chang RF; Chen HH; Chang YC; Huang CS; Chen JH; Lo CM
Magn Reson Imaging; 2016 Jul; 34(6):809-819. PubMed ID: 26968141
[TBL] [Abstract][Full Text] [Related]
30. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304
[TBL] [Abstract][Full Text] [Related]
31. FDG-PET/CT and diffusion-weighted imaging for resected lung cancer: correlation of maximum standardized uptake value and apparent diffusion coefficient value with prognostic factors.
Usuda K; Funasaki A; Sekimura A; Motono N; Matoba M; Doai M; Yamada S; Ueda Y; Uramoto H
Med Oncol; 2018 Apr; 35(5):66. PubMed ID: 29633024
[TBL] [Abstract][Full Text] [Related]
32. Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.
Leithner D; Baltzer PA; Magometschnigg HF; Wengert GJ; Karanikas G; Helbich TH; Weber M; Wadsak W; Pinker K
J Nucl Med; 2016 Oct; 57(10):1518-1522. PubMed ID: 27230924
[TBL] [Abstract][Full Text] [Related]
33. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous whole-body and breast 18F-FDG PET/MRI examinations in patients with breast cancer: a comparison of apparent diffusion coefficients and maximum standardized uptake values.
Sasaki M; Tozaki M; Kubota K; Murakami W; Yotsumoto D; Sagara Y; Ohi Y; Oosako S; Sagara Y
Jpn J Radiol; 2018 Feb; 36(2):122-133. PubMed ID: 29159779
[TBL] [Abstract][Full Text] [Related]
35. Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRI.
Yoon H; Yoon D; Yun M; Choi JS; Park VY; Kim EK; Jeong J; Koo JS; Yoon JH; Moon HJ; Kim S; Kim MJ
PLoS One; 2016; 11(7):e0159949. PubMed ID: 27459480
[TBL] [Abstract][Full Text] [Related]
36. Morphological and Semiquantitative Kinetic Analysis on Dynamic Contrast Enhanced MRI in Triple Negative Breast Cancer Patients.
Gigli S; Amabile MI; David E; De Luca A; Grippo C; Manganaro L; Monti M; Ballesio L
Acad Radiol; 2019 May; 26(5):620-625. PubMed ID: 30145205
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic performance of
Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
[TBL] [Abstract][Full Text] [Related]
38. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.
Kajáry K; Tőkés T; Dank M; Kulka J; Szakáll S; Lengyel Z
Nucl Med Commun; 2015 Jan; 36(1):28-37. PubMed ID: 25299471
[TBL] [Abstract][Full Text] [Related]
39. Features from MRI texture analysis associated with survival outcomes in triple-negative breast cancer patients.
Kamiya S; Satake H; Hayashi Y; Ishigaki S; Ito R; Kawamura M; Taoka T; Iwano S; Naganawa S
Breast Cancer; 2022 Jan; 29(1):164-173. PubMed ID: 34529241
[TBL] [Abstract][Full Text] [Related]
40. Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ-based Comparison With PET/CT.
Pujara AC; Raad RA; Ponzo F; Wassong C; Babb JS; Moy L; Melsaether AN
Breast J; 2016 May; 22(3):264-73. PubMed ID: 26843433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]